🏢 公司NewsroomIDYACodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 09-01(美西日)仅日期·时区推断·⟳ 抓取 18:36:12·⚡ 决策 09-01 19:02:40 +26m28s·56.2 天前
IDEAYA宣布伦敦投资者研发日及9月投行医疗会议日程
来源虽为公司一手，但事件本身只是会议安排和未来拟讨论主题，不是数据读出、监管里程碑、交易合同或业绩更新；现有正文已经足以判断缺少可交易增量，继续查行情或先例不会改变不做结论。
📄 原文IDYA↗ 原文
SOUTH SAN FRANCISCO, Calif. , Sept. 1, 2026 / PRNewswire / -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medi…
不做 IDEAYA Biosciences（IDYA.US）
仅为投资者会议和R&D Day日程预告，未披露临床结果、监管进展、合作金额或业绩增量；无当下可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
IDEAYA Biosciences（IDYA.US）公告参加投行会议并将在11月伦敦R&D Day讨论研发策略及临床前数据，但当前没有披露具体数据质量、临床阶段推进、监管决定、合作金额或财务影响。该类IR日程预告通常只提示未来信息窗口，不构成当下可执行催化，因此回避。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 若11月R&D Day实际披露强临床前组合数据或明确开发路径，届时需按药物阶段和权益重新评估。
先例如何影响了这次决策
对本次决策的影响:先例不会改变结论；关键问题是当前公告没有可交易增量事实。
方向:未使用先例；会议日程预告缺少交易所需的基本面状态迁移。
涨幅量级:无可校准幅度，因为当前事件不是数据读出、审批、合作或业绩类催化。
形态:不适用。
原文全文
展开原文 · 4,415 字
SOUTH SAN FRANCISCO, Calif.
,
Sept. 1, 2026
/
PRNewswire
/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
IDEAYA Biosciences Investor R&D Day in London, United Kingdom
Monday, November 16th, 2026, at 5:00 PM GMT
IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
Advance registration is required for both in-person and virtual attendance. To register, please visit
https://lifescievents.com/event/izl51pw/
Wells Fargo 21
st
Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET, Boston, Massachusetts
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology
Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
Citi
's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
Morgan Stanley 24
th
Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at
https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
,
Sept. 1, 2026
/
PRNewswire
/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
IDEAYA Biosciences Investor R&D Day in London, United Kingdom
Monday, November 16th, 2026, at 5:00 PM GMT
IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
Advance registration is required for both in-person and virtual attendance. To register, please visit
https://lifescievents.com/event/izl51pw/
Wells Fargo 21
st
Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET, Boston, Massachusetts
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology
Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
Citi
's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
Morgan Stanley 24
th
Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at
https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。